ABSTRACT
Mucormycosis (MM) is an invasive fungal infection that causes severe systemic infections and poses health risks and threat to life. Despite its impact on human health, MM infection is neglected and underrepresented compared to other infections. Invasiveness of MM severely compromises systemic and metabolic functions of the hepatic system, degeneration of lungs, trachea, and alveoli epithelial cell with increased fatality rate, and associated risk with therapeutic use of glucocorticoids in COVID-19. In Africa, the prevalence rate remains unknown due to late prognosis and non-reportability of the disease. Hence, there is a need to include MM diagnosis in patients with COVID-19, increase surveillance of emerging clonal strains, and regulate the routine glucocorticoids use in COVID-19 infection therapy. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.